Search

Your search keyword '"Doyle, L. Austin"' showing total 235 results
Start Over Author "Doyle, L. Austin"
235 results on '"Doyle, L. Austin"'

2. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial

Author

Chung, Vincent, McDonough, Shannon, Philip, Philip A, Cardin, Dana, Wang-Gillam, Andrea, Hui, Laifong, Tejani, Mohamedtaki A, Seery, Tara E, Dy, Irene A, Baghdadi, Tareq Al, Hendifar, Andrew E, Doyle, L Austin, Lowy, Andrew M, Guthrie, Katherine A, Blanke, Charles D, and Hochster, Howard S

Subjects
Cancer, Clinical Trials and Supportive Activities, Pancreatic Cancer, Clinical Research, Rare Diseases, Digestive Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Adenocarcinoma, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Benzimidazoles, Disease-Free Survival, Female, Fluorouracil, Heterocyclic Compounds, 3-Ring, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Organoplatinum Compounds, Oxaliplatin, Pancreatic Neoplasms, Proportional Hazards Models, Salvage Therapy, Oncology and Carcinogenesis, Public Health and Health Services
Abstract

ImportanceKRAS mutations are common in pancreatic cancer, but directly targeting the KRAS protein has thus far been unsuccessful. The aim of this trial was to block the MEK and PI3K/AKT pathways downstream of the KRAS protein as an alternate treatment strategy to slow cancer growth and prolong survival. This was the first cooperative group trial to evaluate this strategy using molecularly targeted oral combination therapy for the treatment of chemotherapy-refractory pancreatic cancer.ObjectiveTo compare selumetinib and MK-2206 vs modified FOLFOX (mFOLFOX) in patients with metastatic pancreatic cancer for whom gemcitabine-based therapy had failed.Design, setting, and participantsSWOG S1115 was a randomized phase 2 clinical trial. Between September 2012 and May 2014, 137 patients with metastatic pancreatic adenocarcinoma for whom gemcitabine-based chemotherapy had failed were randomized to selumetinib plus MK-2206 or mFOLFOX. Patients were randomized in a 1:1 fashion and stratified according to duration of prior systemic therapy and presence of liver metastases.InterventionsPatients received selumetinib 100 mg orally per day plus MK-2206 135 mg orally once per week or mFOLFOX (oxaliplatin, 85 mg/m2 intravenous, and fluorouracil, 2400 mg/m2 intravenous infusion over 46-48 hours) on days 1 and 15 of a 28-day cycle.Main outcomes and measuresThe primary end point of the study was overall survival. Secondary objectives included evaluating toxic effects, objective tumor response, and progression-free survival.ResultsThere were 58 patients in the selumetinib plus MK-2206 (experimental) arm (60% male; median [range] age, 69 [54-88] years) and 62 patients in the mFOLFOX arm (35% male; median [range] age, 65 [34-82] years). In the experimental arm, median overall survival was shorter (3.9 vs 6.7 months; HR, 1.37; 95% CI, 0.90-2.08; P = .15), as was median progression-free survival (1.9 vs 2.0 months; HR, 1.61; 95% CI, 1.07-2.43; P = .02). One vs 5 patients had a partial response and 12 vs 14 patients had stable disease in the experimental arm vs mFOLFOX arm. Grade 3 or higher toxic effects were observed in 39 patients treated with selumetinib and MK-2206 vs 23 patients treated with mFOLFOX. More patients in the experimental arm discontinued therapy due to adverse events (13 vs 7 patients).Conclusions and relevanceDual targeting of the MEK and PI3K/AKT pathways downstream of KRAS by selumetinib plus MK-2206 did not improve overall survival in patients with metastatic pancreatic adenocarcinoma for whom gemcitabine-based chemotherapy had failed. This was the first randomized prospective evaluation of mFOLFOX in the US population that showed comparable results to CONKO-003 and PANCREOX.Trial registrationclinicaltrials.gov Identifier: NCT01658943.

Published
2017

3. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

Author

Konstantinopoulos, Panagiotis A, Cheng, Su-Chun, Wahner Hendrickson, Andrea E, Penson, Richard T, Schumer, Susan T, Doyle, L Austin, Lee, Elizabeth K, Kohn, Elise C, Duska, Linda R, Crispens, Marta A, Olawaiye, Alexander B, Winer, Ira S, Barroilhet, Lisa M, Fu, Siqing, McHale, Michael T, Schilder, Russell J, Färkkilä, Anniina, Chowdhury, Dipanjan, Curtis, Jennifer, Quinn, Roxanne S, Bowes, Brittany, D'Andrea, Alan D, Shapiro, Geoffrey I, and Matulonis, Ursula A

Published
2020
Full Text
View/download PDF

4. Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

Author

Jain, Nitin, Curran, Emily, Iyengar, Neil M, Diaz-Flores, Ernesto, Kunnavakkam, Rangesh, Popplewell, Leslie, Kirschbaum, Mark H, Karrison, Theodore, Erba, Harry P, Green, Margaret, Poire, Xavier, Koval, Greg, Shannon, Kevin, Reddy, Poluru L, Joseph, Loren, Atallah, Ehab L, Dy, Philip, Thomas, Sachdev P, Smith, Scott E, Doyle, L Austin, Stadler, Walter M, Larson, Richard A, Stock, Wendy, and Odenike, Olatoyosi

Subjects
Hematology, Cancer, Rare Diseases, Genetics, Childhood Leukemia, Clinical Research, Pediatric Cancer, Pediatric, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Benzimidazoles, Female, Genes, ras, Humans, Leukemia, Myeloid, Acute, Male, Middle Aged, Mitogen-Activated Protein Kinase Kinases, Mutation, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-kit, Treatment Outcome, fms-Like Tyrosine Kinase 3, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeThe clinical relevance of targeting the RAS/RAF/MEK/ERK pathway, activated in 70% to 80% of patients with acute myelogenous leukemia (AML), is unknown.Experimental designSelumetinib is an oral small-molecule inhibitor of MAP-ERK kinase (MEK)-1/2. Forty-seven patients with relapsed/refractory AML or 60 years old or more with untreated AML were enrolled on a phase II study. Patients were stratified by FLT3 ITD mutation status. The primary endpoint was response rate (complete, partial, and minor). Leukemia cells were analyzed for extracellular signal-regulated kinase (ERK) and mTOR phosphorylation.ResultsCommon drug-related toxicities were grade 1-2 diarrhea, fatigue, nausea, vomiting, and skin rash. In the FLT3 wild-type cohort, six of 36 (17%) patients had a response [one partial response, three minor responses, two unconfirmed minor responses (uMR)]. No patient with FLT3 ITD responded. NRAS and KRAS mutations were detected in 7% and 2% of patients, respectively. The sole patient with KRAS mutation had uMR with hematologic improvement in platelets. Baseline p-ERK activation was observed in 85% of patients analyzed but did not correlate with a response. A single-nucleotide polymorphism (SNP) rs3733542 in exon 18 of the KIT gene was detected in significantly higher number of patients with response/stable disease compared with nonresponders (60% vs. 23%; P = 0.027).ConclusionsSelumetinib is associated with modest single-agent antileukemic activity in advanced AML. However, given its favorable toxicity profile, combination with drugs that target other signaling pathways in AML should be considered. The potential association of SNP rs3733542 in exon 18 of the KIT gene with antileukemic activity of selumetinib is intriguing, but will require validation in larger trials.

Published
2014

7. Supplementary Table 1 from Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

Author

Jain, Nitin, primary, Curran, Emily, primary, Iyengar, Neil M., primary, Diaz-Flores, Ernesto, primary, Kunnavakkam, Rangesh, primary, Popplewell, Leslie, primary, Kirschbaum, Mark H., primary, Karrison, Theodore, primary, Erba, Harry P., primary, Green, Margaret, primary, Poire, Xavier, primary, Koval, Greg, primary, Shannon, Kevin, primary, Reddy, Poluru L., primary, Joseph, Loren, primary, Atallah, Ehab L., primary, Dy, Philip, primary, Thomas, Sachdev P., primary, Smith, Scott E., primary, Doyle, L. Austin, primary, Stadler, Walter M., primary, Larson, Richard A., primary, Stock, Wendy, primary, and Odenike, Olatoyosi, primary

Published
2023
Full Text
View/download PDF

8. Supplemental Figure 1 from A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report

Author

Fouladi, Maryam, primary, Perentesis, John P., primary, Wagner, Lars M., primary, Vinks, Alexander A., primary, Reid, Joel M., primary, Ahern, Charlotte, primary, Thomas, George, primary, Mercer, Carol A., primary, Krueger, Darcy A., primary, Houghton, Peter J., primary, Doyle, L. Austin, primary, Chen, Helen, primary, Weigel, Brenda, primary, and Blaney, Susan M., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure Legends from Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

Author

Konopleva, Marina Y., primary, Walter, Roland B., primary, Faderl, Stefan H., primary, Jabbour, Elias J., primary, Zeng, Zhihong, primary, Borthakur, Gautam, primary, Huang, Xuelin, primary, Kadia, Tapan M., primary, Ruvolo, Peter P., primary, Feliu, Jennie B., primary, Lu, Hongbo, primary, Debose, LaKiesha, primary, Burger, Jan A., primary, Andreeff, Michael, primary, Liu, Wenbin, primary, Baggerly, Keith A., primary, Kornblau, Steven M., primary, Doyle, L. Austin, primary, Estey, Elihu H., primary, and Kantarjian, Hagop M., primary

Published
2023
Full Text
View/download PDF

12. Supplemental Table 1 from A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report

Author

Fouladi, Maryam, primary, Perentesis, John P., primary, Wagner, Lars M., primary, Vinks, Alexander A., primary, Reid, Joel M., primary, Ahern, Charlotte, primary, Thomas, George, primary, Mercer, Carol A., primary, Krueger, Darcy A., primary, Houghton, Peter J., primary, Doyle, L. Austin, primary, Chen, Helen, primary, Weigel, Brenda, primary, and Blaney, Susan M., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 4 from Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

Author

Konopleva, Marina Y., primary, Walter, Roland B., primary, Faderl, Stefan H., primary, Jabbour, Elias J., primary, Zeng, Zhihong, primary, Borthakur, Gautam, primary, Huang, Xuelin, primary, Kadia, Tapan M., primary, Ruvolo, Peter P., primary, Feliu, Jennie B., primary, Lu, Hongbo, primary, Debose, LaKiesha, primary, Burger, Jan A., primary, Andreeff, Michael, primary, Liu, Wenbin, primary, Baggerly, Keith A., primary, Kornblau, Steven M., primary, Doyle, L. Austin, primary, Estey, Elihu H., primary, and Kantarjian, Hagop M., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 1 from Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

Author

Konopleva, Marina Y., primary, Walter, Roland B., primary, Faderl, Stefan H., primary, Jabbour, Elias J., primary, Zeng, Zhihong, primary, Borthakur, Gautam, primary, Huang, Xuelin, primary, Kadia, Tapan M., primary, Ruvolo, Peter P., primary, Feliu, Jennie B., primary, Lu, Hongbo, primary, Debose, LaKiesha, primary, Burger, Jan A., primary, Andreeff, Michael, primary, Liu, Wenbin, primary, Baggerly, Keith A., primary, Kornblau, Steven M., primary, Doyle, L. Austin, primary, Estey, Elihu H., primary, and Kantarjian, Hagop M., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure 1 from Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

Author

Jain, Nitin, primary, Curran, Emily, primary, Iyengar, Neil M., primary, Diaz-Flores, Ernesto, primary, Kunnavakkam, Rangesh, primary, Popplewell, Leslie, primary, Kirschbaum, Mark H., primary, Karrison, Theodore, primary, Erba, Harry P., primary, Green, Margaret, primary, Poire, Xavier, primary, Koval, Greg, primary, Shannon, Kevin, primary, Reddy, Poluru L., primary, Joseph, Loren, primary, Atallah, Ehab L., primary, Dy, Philip, primary, Thomas, Sachdev P., primary, Smith, Scott E., primary, Doyle, L. Austin, primary, Stadler, Walter M., primary, Larson, Richard A., primary, Stock, Wendy, primary, and Odenike, Olatoyosi, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Materials from Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms

Author

Holkova, Beata, primary, Kmieciak, Maciej, primary, Perkins, E. Brent, primary, Bose, Prithviraj, primary, Baz, Rachid C., primary, Roodman, G. David, primary, Stuart, Robert K., primary, Ramakrishnan, Viswanathan, primary, Wan, Wen, primary, Peer, Cody J., primary, Dawson, Jana, primary, Kang, Loveleen, primary, Honeycutt, Connie, primary, Tombes, Mary Beth, primary, Shrader, Ellen, primary, Weir-Wiggins, Caryn, primary, Wellons, Martha, primary, Sankala, Heidi, primary, Hogan, Kevin T., primary, Colevas, A. Dimitrios, primary, Doyle, L. Austin, primary, Figg, William D., primary, Coppola, Domenico, primary, Roberts, John D., primary, Sullivan, Daniel, primary, and Grant, Steven, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure 3 from Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

Author

Konopleva, Marina Y., primary, Walter, Roland B., primary, Faderl, Stefan H., primary, Jabbour, Elias J., primary, Zeng, Zhihong, primary, Borthakur, Gautam, primary, Huang, Xuelin, primary, Kadia, Tapan M., primary, Ruvolo, Peter P., primary, Feliu, Jennie B., primary, Lu, Hongbo, primary, Debose, LaKiesha, primary, Burger, Jan A., primary, Andreeff, Michael, primary, Liu, Wenbin, primary, Baggerly, Keith A., primary, Kornblau, Steven M., primary, Doyle, L. Austin, primary, Estey, Elihu H., primary, and Kantarjian, Hagop M., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure 2B from Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

Author

Konopleva, Marina Y., primary, Walter, Roland B., primary, Faderl, Stefan H., primary, Jabbour, Elias J., primary, Zeng, Zhihong, primary, Borthakur, Gautam, primary, Huang, Xuelin, primary, Kadia, Tapan M., primary, Ruvolo, Peter P., primary, Feliu, Jennie B., primary, Lu, Hongbo, primary, Debose, LaKiesha, primary, Burger, Jan A., primary, Andreeff, Michael, primary, Liu, Wenbin, primary, Baggerly, Keith A., primary, Kornblau, Steven M., primary, Doyle, L. Austin, primary, Estey, Elihu H., primary, and Kantarjian, Hagop M., primary

Published
2023
Full Text
View/download PDF

22. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation

Author

Xing, Yan, Lin, Nancy U., Maurer, Matthew A., Chen, Huiqin, Mahvash, Armeen, Sahin, Aysegul, Akcakanat, Argun, Li, Yisheng, Abramson, Vandana, Litton, Jennifer, Chavez-MacGregor, Mariana, Valero, Vicente, Piha-Paul, Sarina A., Hong, David, Do, Kim-Anh, Tarco, Emily, Riall, Dianna, Eterovic, Agda Karina, Wulf, Gerburg M., Cantley, Lewis C., Mills, Gordon B., Doyle, L. Austin, Winer, Eric, Hortobagyi, Gabriel N., Gonzalez-Angulo, Ana Maria, and Meric-Bernstam, Funda

Published
2019
Full Text
View/download PDF

23. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

Author

Schwartz, Gary K, Tap, William D, Qin, Li-Xuan, Livingston, Michael B, Undevia, Samir D, Chmielowski, Bartosz, Agulnik, Mark, Schuetze, Scott M, Reed, Damon R, Okuno, Scott H, Ludwig, Joseph A, Keedy, Vicki, Rietschel, Petra, Kraft, Andrew S, Adkins, Douglas, Van Tine, Brian A, Brockstein, Bruce, Yim, Vincent, Bitas, Christiana, Abdullah, Abdul, Antonescu, Cristina R, Condy, Mercedes, Dickson, Mark A, Vasudeva, Shyamprasad Deraje, Ho, Alan L, Doyle, L Austin, Chen, Helen X, and Maki, Robert G

Published
2013
Full Text
View/download PDF

24. A Phase 2 Trial of Flavopiridol (Alvocidib) and Cisplatin in Platin-Resistant Ovarian and Primary Peritoneal Carcinoma: MC0261

Author

Bible, Keith C., Peethambaram, Prema P., Oberg, Ann L., Maples, William, Groteluschen, David L., Boente, Matthew, Burton, Jill K., Gomez Dahl, Leigh C., Tibodeau, Jennifer D., Isham, Crescent R., Maguire, Jacie L., Shridhar, Viji, Kukla, Andrea K., Voll, Kalli J., Mauer, Mathew J., Colevas, Alexander D., Wright, John, Doyle, L. Austin, and Erlichman, Charles

Published
2012
Full Text
View/download PDF

26. Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study

Author

Fangusaro, Jason R, primary, Onar-Thomas, Arzu, additional, Poussaint, Tina Young, additional, Wu, Shengjie, additional, Ligon, Azra H, additional, Lindeman, Neal Ian, additional, Banerjee, Anuradha, additional, Packer, Roger, additional, Kilburn, Lindsay B, additional, Pollack, Ian F, additional, Qaddoumi, Ibrahim A, additional, Fisher, Paul Graham, additional, Dhall, Girish, additional, Baxter, Patricia Ann, additional, Kreissman, Susan G, additional, Doyle, L Austin, additional, Smith, Malcolm A, additional, Fouladi, Maryam, additional, and Dunkel, Ira J, additional

Published
2022
Full Text
View/download PDF

27. Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias

Author

Karp, Judith E., Smith, B. Douglas, Resar, Linda S., Greer, Jacqueline M., Blackford, Amanda, Zhao, Ming, Moton-Nelson, Dwella, Alino, Katrina, Levis, Mark J., Gore, Steven D., Joseph, Biju, Carraway, Hetty, McDevitt, Michael A., Bagain, Lorena, Mackey, Karen, Briel, Janet, Doyle, L. Austin, Wright, John J., and Rudek, Michelle A.

Published
2011
Full Text
View/download PDF

30. Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies

Author

Hubbard, Joleen M., primary, Yin, Jun, additional, Schenk, Erin L., additional, Qin, Rui, additional, Reid, Joel M., additional, Strand, Carrie, additional, Fiskum, Jack, additional, Menefee, Michael, additional, Lin, Grace, additional, Doyle, L. Austin, additional, Ivy, Percy, additional, Erlichman, Charles, additional, Adjei, Alex, additional, Haluska, Paul, additional, and Costello, Brian A., additional

Published
2021
Full Text
View/download PDF

31. Abstract 1072: Combination screening of DNA damaging agents temozolomide and trabectedin with inhibitors of DNA repair using a complex spheroid model with a panel of patient-derived and established tumor cell lines

Author

Coussens, Nathan P., primary, Parchment, Ralph E., additional, Moscow, Jeffrey A., additional, Doyle, L. Austin, additional, Delosh, René, additional, Laudeman, Julie, additional, Reinhart, Russell, additional, Ogle, Chad, additional, Silvers, Thomas, additional, Dexheimer, Thomas S., additional, Morris, Joel, additional, Teicher, Beverly A., additional, and Doroshow, James H., additional

Published
2021
Full Text
View/download PDF

34. Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor

Author

Kalinsky, Kevin, primary, Hong, Fangxin, additional, McCourt, Carolyn K., additional, Sachdev, Jasgit C., additional, Mitchell, Edith P., additional, Zwiebel, James A., additional, Doyle, L. Austin, additional, McShane, Lisa M., additional, Li, Shuli, additional, Gray, Robert J., additional, Rubinstein, Larry V., additional, Patton, David, additional, Williams, Paul M., additional, Hamilton, Stanley R., additional, Conley, Barbara A., additional, O’Dwyer, Peter J., additional, Harris, Lyndsay N., additional, Arteaga, Carlos L., additional, Chen, Alice P., additional, and Flaherty, Keith T., additional

Published
2021
Full Text
View/download PDF

36. Abstract B24: Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation

Author

Xing, Yan, primary, Lin, Nancy U., additional, Mauer, Mathew, additional, Chen, Huiqin, additional, Mahvash, Armeen, additional, Sahin, Aysegul, additional, Akcakanat, Argun, additional, Li, Yisheng, additional, Abraham, Vandana, additional, Litton, Jennifer, additional, Chavez-McGregor, Mariana, additional, Valero, Vicente, additional, Piha-Paul, Sarina A., additional, Hong, David, additional, Do, Kim-Anh, additional, Tarco, Emily, additional, Riall, Dianna, additional, Eterovic, Karina Agda, additional, Cantley, Lewis, additional, Mills, Gordon B., additional, Doyle, L. Austin, additional, Winer, Eric, additional, Hortobagyi, Gabriel, additional, Gonzalez-Angulo, Ana Maria, additional, and Meric-Bernstam, Funda, additional

Published
2020
Full Text
View/download PDF

37. A phase II study of M6620 in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.

Author

Choudhury, Atish Dipankar, primary, Xie, Wanling, additional, Parikh, Mamta, additional, Lee, Daniel, additional, Kessler, Elizabeth R, additional, Einstein, David Johnson, additional, Kochupurakkal, Bose, additional, Mouw, Kent William, additional, Van Allen, Eliezer Mendel, additional, Doyle, L. Austin, additional, D'Andrea, Alan D., additional, Taplin, Mary-Ellen, additional, and Shapiro, Geoffrey, additional

Published
2020
Full Text
View/download PDF

38. Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)

Author

Lee, Elizabeth K., primary, Tan-Wasielewski, Zhenying, additional, Aghajanian, Carol, additional, Coleman, Robert L., additional, Curtis, Jennifer, additional, Hirsch, Michelle S., additional, Matulonis, Ursula A., additional, Cantley, Lewis C., additional, Mills, Gordon B., additional, Doyle, L. Austin, additional, and Liu, Joyce F., additional

Published
2020
Full Text
View/download PDF

39. Selumetinib in Children with Inoperable Plexiform Neurofibromas

Author

Gross, Andrea M., primary, Wolters, Pamela L., additional, Dombi, Eva, additional, Baldwin, Andrea, additional, Whitcomb, Patricia, additional, Fisher, Michael J., additional, Weiss, Brian, additional, Kim, AeRang, additional, Bornhorst, Miriam, additional, Shah, Amish C., additional, Martin, Staci, additional, Roderick, Marie C., additional, Pichard, Dominique C., additional, Carbonell, Amanda, additional, Paul, Scott M., additional, Therrien, Janet, additional, Kapustina, Oxana, additional, Heisey, Kara, additional, Clapp, D. Wade, additional, Zhang, Chi, additional, Peer, Cody J., additional, Figg, William D., additional, Smith, Malcolm, additional, Glod, John, additional, Blakeley, Jaishri O., additional, Steinberg, Seth M., additional, Venzon, David J., additional, Doyle, L. Austin, additional, and Widemann, Brigitte C., additional

Published
2020
Full Text
View/download PDF

47. Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)

Author

Zeidner, Joshua F., Foster, Matthew C., Blackford, Amanda L., Litzow, Mark R., Morris, Lawrence E., Strickland, Stephen A., Lancet, Jeffrey E., Bose, Prithviraj, Levy, M. Yair, Tibes, Raoul, Gojo, Ivana, Gocke, Christopher D., Rosner, Gary L., Little, Richard F., Wright, John J., Doyle, L. Austin, Smith, B. Douglas, and Karp, Judith E.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results